EV/EBITDA Ratio: 19.11x
Is the EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 19.11x is 14% above its 5-year average of 16.78x, around the middle of its 5-year range (7.20x–26.40x).
As of Saturday, June 27, 2026. 42.72% above its 12-month average of 13.39x.
NRC EV/EBITDA Ratio Chart
NRC Average EV/EBITDA Ratio Chart
NRC Current vs Average EV/EBITDA Ratio Chart
NRC EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
19.11x
EV/EBITDA RATIO AVG TTM
13.39x
EV/EBITDA RATIO AVG 3Y
15.09x
EV/EBITDA RATIO AVG 5Y
16.78x
EV/EBITDA RATIO AVG 10Y
20.40x
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+42.72%
CURRENT VS 3Y AVG
+26.65%
CURRENT VS 5Y AVG
+13.87%
CURRENT VS 10Y AVG
-6.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NRC Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| National Research Corporation (NRC) | $468.99M | 19.11x | 13.39x | 15.09x | 16.78x |
| Shoulder Innovations, Inc. (SI)vs › | $472.62M | N/A | N/A | N/A | N/A |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.51B | 42.51x | 37.00x | 270.07x | 270.07x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.21B | 7.64x | 7.50x | 41.47x | 29.03x |
| TransMedics Group, Inc. (TMDX)vs › | $2.37B | 22.61x | 42.68x | 93.84x | 93.84x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.57B | 87.10x | 66.28x | 327.19x | 327.19x |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | 136.96x | 60.29x | 46.36x | 46.36x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.13B | 20.52x | 20.87x | 19.59x | 22.00x |
| Universal Health Services, Inc. (UHS)vs › | $9.12B | 5.25x | 6.96x | 8.30x | 8.25x |
EV/EBITDA vs. its own history
At 19.1, EV/EBITDA is in its normal range, sitting higher than 58% of its 13-year history.
13-year low
5.5
median
17.2
13-year high
41.2
EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for National Research Corporation (NRC)?
- The EV/EBITDA ratio for NRC stock is 19.11x.
- Is National Research Corporation's EV/EBITDA ratio high or low?
- The EV/EBITDA ratio of 19.11x is 14% above its 5-year average of 16.78x, around the middle of its 5-year range (7.20x–26.40x).
- What is the TTM average EV/EBITDA ratio for National Research Corporation (NRC)?
- The TTM average EV/EBITDA ratio for NRC stock is 13.39x.
- What is the 3Y average EV/EBITDA ratio for National Research Corporation (NRC)?
- The 3Y average EV/EBITDA ratio for NRC stock is 15.09x.
- What is the 5Y average EV/EBITDA ratio for National Research Corporation (NRC)?
- The 5Y average EV/EBITDA ratio for NRC stock is 16.78x.
- What is the 10Y average EV/EBITDA ratio for National Research Corporation (NRC)?
- The 10Y average EV/EBITDA ratio for NRC stock is 20.40x.
NRC EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-26 | 19.11x |
| 2026-06-25 | 18.90x |
| 2026-06-24 | 19.02x |
| 2026-06-23 | 18.50x |
| 2026-06-22 | 18.07x |
| 2026-06-18 | 17.32x |
| 2026-06-17 | 16.70x |
| 2026-06-16 | 17.26x |
| 2026-06-15 | 17.14x |
| 2026-06-12 | 17.52x |
| 2026-06-11 | 17.52x |
| 2026-06-10 | 19.48x |
| 2026-06-09 | 18.27x |
| 2026-06-08 | 17.94x |
| 2026-06-05 | 17.79x |
| 2026-06-04 | 18.27x |
| 2026-06-03 | 17.71x |
| 2026-06-02 | 18.15x |
| 2026-06-01 | 18.67x |
| 2026-05-29 | 18.10x |
| 2026-05-28 | 18.20x |
| 2026-05-27 | 17.78x |
| 2026-05-26 | 17.71x |
| 2026-05-22 | 17.75x |
| 2026-05-21 | 17.71x |
| 2026-05-20 | 17.89x |
| 2026-05-19 | 17.49x |
| 2026-05-18 | 17.48x |
| 2026-05-15 | 17.38x |
| 2026-05-14 | 17.63x |
| 2026-05-13 | 17.42x |
| 2026-05-12 | 17.83x |
| 2026-05-11 | 17.45x |
| 2026-05-08 | 17.49x |
| 2026-05-07 | 17.47x |
| 2026-05-06 | 16.78x |
| 2026-05-05 | 16.01x |
| 2026-05-04 | 15.63x |
| 2026-05-01 | 15.05x |
| 2026-04-30 | 14.36x |
| 2026-04-29 | 14.42x |
| 2026-04-28 | 14.63x |
| 2026-04-27 | 14.83x |
| 2026-04-24 | 14.92x |
| 2026-04-23 | 14.93x |
| 2026-04-22 | 15.11x |
| 2026-04-21 | 14.88x |
| 2026-04-20 | 15.60x |
| 2026-04-17 | 15.49x |
| 2026-04-16 | 15.20x |
| 2026-04-15 | 15.36x |
| 2026-04-14 | 14.78x |
| 2026-04-13 | 14.62x |
| 2026-04-10 | 14.37x |
| 2026-04-09 | 14.79x |
| 2026-04-08 | 14.94x |
| 2026-04-07 | 14.78x |
| 2026-04-06 | 14.99x |
| 2026-04-02 | 14.86x |
| 2026-04-01 | 14.99x |
| 2026-03-31 | 14.73x |
| 2026-03-30 | 14.85x |
| 2026-03-27 | 14.84x |
| 2026-03-26 | 15.12x |
| 2026-03-25 | 14.88x |
| 2026-03-24 | 15.07x |
| 2026-03-23 | 15.12x |
| 2026-03-20 | 14.98x |
| 2026-03-19 | 14.97x |
| 2026-03-18 | 15.16x |
| 2026-03-17 | 15.28x |
| 2026-03-16 | 15.04x |
| 2026-03-13 | 14.40x |
| 2026-03-12 | 14.39x |
| 2026-03-11 | 14.03x |
| 2026-03-10 | 14.22x |
| 2026-03-09 | 13.28x |
| 2026-03-06 | 13.01x |
| 2026-03-05 | 12.61x |
| 2026-03-04 | 10.85x |
| 2026-03-03 | 11.02x |
| 2026-03-02 | 11.32x |
| 2026-02-27 | 11.03x |
| 2026-02-26 | 11.05x |
| 2026-02-25 | 10.72x |
| 2026-02-24 | 10.43x |
| 2026-02-23 | 10.44x |
| 2026-02-20 | 11.21x |
| 2026-02-19 | 10.41x |
| 2026-02-18 | 10.33x |
| 2026-02-17 | 10.13x |
| 2026-02-13 | 10.16x |
| 2026-02-12 | 10.66x |
| 2026-02-11 | 11.26x |
| 2026-02-10 | 11.79x |
| 2026-02-09 | 12.32x |
| 2026-02-06 | 12.69x |
| 2026-02-05 | 12.68x |
| 2026-02-04 | 12.25x |
| 2026-02-03 | 13.79x |
| 2026-02-02 | 16.59x |
| 2026-01-30 | 15.57x |
| 2026-01-29 | 15.38x |
| 2026-01-28 | 15.23x |
| 2026-01-27 | 15.58x |
| 2026-01-26 | 15.88x |
| 2026-01-23 | 16.05x |
| 2026-01-22 | 16.67x |
| 2026-01-21 | 16.97x |
| 2026-01-20 | 16.59x |
| 2026-01-16 | 16.80x |
| 2026-01-15 | 16.20x |
| 2026-01-14 | 15.90x |
| 2026-01-13 | 15.93x |
| 2026-01-12 | 15.63x |
| 2026-01-09 | 15.17x |
| 2026-01-08 | 15.02x |
| 2026-01-07 | 14.63x |
| 2026-01-06 | 14.89x |
| 2026-01-05 | 14.56x |
| 2026-01-02 | 14.06x |
| 2025-12-31 | 14.54x |
| 2025-12-30 | 14.47x |
| 2025-12-29 | 14.68x |
| 2025-12-26 | 14.47x |
| 2025-12-24 | 14.57x |
| 2025-12-23 | 14.70x |
| 2025-12-22 | 14.62x |
| 2025-12-19 | 14.50x |
| 2025-12-18 | 14.89x |
| 2025-12-17 | 14.46x |
| 2025-12-16 | 14.32x |
| 2025-12-15 | 14.04x |
| 2025-12-12 | 13.80x |
| 2025-12-11 | 13.66x |
| 2025-12-10 | 13.34x |
| 2025-12-09 | 12.76x |
| 2025-12-08 | 12.63x |
| 2025-12-05 | 12.65x |
| 2025-12-04 | 12.94x |
| 2025-12-03 | 12.84x |
| 2025-12-02 | 12.86x |
| 2025-12-01 | 13.25x |
| 2025-11-28 | 13.38x |
| 2025-11-26 | 13.56x |
| 2025-11-25 | 14.05x |
| 2025-11-24 | 13.59x |
| 2025-11-21 | 13.82x |
| 2025-11-20 | 13.13x |
| 2025-11-19 | 12.93x |
| 2025-11-18 | 12.76x |
| 2025-11-17 | 12.74x |
| 2025-11-14 | 12.23x |
| 2025-11-13 | 12.43x |
| 2025-11-12 | 12.36x |
| 2025-11-11 | 12.03x |
| 2025-11-10 | 11.74x |
| 2025-11-07 | 11.88x |
| 2025-11-06 | 11.75x |
| 2025-11-05 | 11.57x |
| 2025-11-04 | 11.38x |
| 2025-11-03 | 11.02x |
| 2025-10-31 | 11.10x |
| 2025-10-30 | 10.92x |
| 2025-10-29 | 11.16x |
| 2025-10-28 | 11.02x |
| 2025-10-27 | 9.81x |
| 2025-10-24 | 9.97x |
| 2025-10-23 | 9.97x |
| 2025-10-22 | 10.13x |
| 2025-10-21 | 10.25x |
| 2025-10-20 | 10.15x |
| 2025-10-17 | 9.93x |
| 2025-10-16 | 9.98x |
| 2025-10-15 | 9.83x |
| 2025-10-14 | 9.87x |
| 2025-10-13 | 9.85x |
| 2025-10-10 | 9.85x |
| 2025-10-09 | 10.01x |
| 2025-10-08 | 10.14x |
| 2025-10-07 | 10.21x |
| 2025-10-06 | 10.24x |
| 2025-10-03 | 10.33x |
| 2025-10-02 | 10.50x |
| 2025-10-01 | 10.53x |
| 2025-09-30 | 10.71x |
| 2025-09-29 | 10.71x |
| 2025-09-26 | 11.06x |
| 2025-09-25 | 11.42x |
| 2025-09-24 | 11.89x |
| 2025-09-23 | 11.97x |
| 2025-09-22 | 12.33x |
| 2025-09-19 | 12.05x |
| 2025-09-18 | 12.78x |
| 2025-09-17 | 12.79x |
| 2025-09-16 | 12.89x |
| 2025-09-15 | 12.98x |
| 2025-09-12 | 12.86x |
| 2025-09-11 | 12.98x |
| 2025-09-10 | 12.78x |
| 2025-09-09 | 12.94x |
| 2025-09-08 | 12.69x |
| 2025-09-05 | 12.45x |
| 2025-09-04 | 12.16x |
| 2025-09-03 | 12.01x |
| 2025-09-02 | 12.23x |
| 2025-08-29 | 11.98x |
| 2025-08-28 | 11.95x |
| 2025-08-27 | 12.51x |
| 2025-08-26 | 12.44x |
| 2025-08-25 | 12.36x |
| 2025-08-22 | 12.43x |
| 2025-08-21 | 11.86x |
| 2025-08-20 | 12.67x |
| 2025-08-19 | 12.96x |
| 2025-08-18 | 12.53x |
| 2025-08-15 | 12.39x |
| 2025-08-14 | 12.19x |
| 2025-08-13 | 12.57x |
| 2025-08-12 | 12.54x |
| 2025-08-11 | 12.25x |
| 2025-08-08 | 12.25x |
| 2025-08-07 | 9.73x |
| 2025-08-06 | 9.43x |
| 2025-08-05 | 9.23x |
| 2025-08-04 | 9.15x |
| 2025-08-01 | 8.55x |
| 2025-07-31 | 8.50x |
| 2025-07-30 | 8.58x |
| 2025-07-29 | 8.93x |
| 2025-07-28 | 9.31x |
| 2025-07-25 | 9.28x |
| 2025-07-24 | 9.41x |
| 2025-07-23 | 9.75x |
| 2025-07-22 | 9.43x |
| 2025-07-21 | 9.37x |
| 2025-07-18 | 9.46x |
| 2025-07-17 | 9.87x |
| 2025-07-16 | 9.87x |
| 2025-07-15 | 9.96x |
| 2025-07-14 | 10.11x |
| 2025-07-11 | 10.44x |
| 2025-07-10 | 10.61x |
| 2025-07-09 | 10.87x |
| 2025-07-08 | 10.94x |
| 2025-07-07 | 10.72x |
| 2025-07-03 | 11.02x |
| 2025-07-02 | 10.76x |
| 2025-07-01 | 10.83x |
| 2025-06-30 | 10.90x |
| 2025-06-27 | 10.83x |
| 2025-06-26 | 10.56x |
| 2025-06-25 | 10.93x |
| 2025-06-24 | 11.15x |
| 2025-06-23 | 11.02x |
| 2025-06-20 | 10.76x |
| 2025-06-18 | 10.92x |
| 2025-06-17 | 10.89x |
| 2025-06-16 | 10.81x |
| 2025-06-13 | 10.48x |
Showing the most recent 260 of 3,293 data points. The chart above shows the full history.
Related Metrics
About National Research Corporation
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trent Green